Halozyme Plummets After U.S. Regulators Reject Drug

Halozyme Therapeutics Inc. fell the most in its eight-year history after an immune deficiency treatment it developed with Baxter International Inc. was rejected by U.S. regulators who also halted a separate clinical trial involving Halozyme’s part of the combination therapy.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.